CRISM Therapeutics Corporation
LLSE:CRTXTotal Valuation
GBXAs of December 31, 2025, CRISM Therapeutics Corporation carries a market capitalization of 517.35M, placing it among publicly traded companies globally. Its enterprise value stands at 404.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 517.35M |
| Enterprise Value | 404.55M |
Share Statistics
As of December 31, 2025, CRISM Therapeutics Corporation has 51.74M shares outstanding.
| Shares Outstanding | 51.74M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | 3.65 |
| P/TBV Ratio | 3.94 |
Financial Position
As of December 31, 2025, CRISM Therapeutics Corporation maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.35 |
| Quick Ratio | 2.96 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 49.00 |
Stock Price Statistics
GBXAs of the close on October 23, 2026, CRISM Therapeutics Corporation's stock has declined approximately 14.29% over the past 52 weeks. The 50-day moving average sits at 10.17, while the 200-day moving average is 11.16.
| 52-Week Price Change | -14.29% |
| 50-Day Moving Average | 10.17 |
| 200-Day Moving Average | 11.16 |
Balance Sheet
GBXThese figures are as of December 31, 2025. Total book value stands at 141.60M, with working capital of 127.60M providing operational flexibility.
| Cash & Cash Equivalents | 112.80M |
| Net Debt | -112.80M |
| Equity (Book Value) | 141.60M |
| Book Value Per Share | 2.74 |
| Working Capital | 127.60M |
Stock Splits
CRISM Therapeutics Corporation's most recent stock split took place on May 31, 2024 with a 160:1 split ratio.
| Last Split Date | 5/31/2024 |
| Split Ratio | 160:1 |